Syngene International Limited (NSE:SYNGENE)
India · Delayed Price · Currency is INR 703.25
-10.75 (-1.51%)
Aug 1, 2025, 3:29 PM IST
HashiCorp Revenue
Syngene International had revenue of 8.75B INR in the quarter ending June 30, 2025, with 10.74% growth. This brings the company's revenue in the last twelve months to 37.27B, up 7.41% year-over-year. In the fiscal year ending March 31, 2025, Syngene International had annual revenue of 36.42B with 4.41% growth.
Revenue (ttm)
37.27B
Revenue Growth
+7.41%
P/S Ratio
7.51
Revenue / Employee
5.71M
Employees
6,533
Market Cap
279.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 36.42B | 1.54B | 4.41% |
| Mar 31, 2024 | 34.89B | 2.96B | 9.26% |
| Mar 31, 2023 | 31.93B | 5.89B | 22.61% |
| Mar 31, 2022 | 26.04B | 4.20B | 19.22% |
| Mar 31, 2021 | 21.84B | 1.72B | 8.57% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.86B |
Syngene International News
- 8 days ago - Goldman Sachs maintains buy on Syngene, bullish on FY26 early-teens growth outlook, sees 15.5% upside on Q1 beat and rising CRO-led margin gains - Business Upturn
- 9 days ago - Syngene Q1 profit up 59% to Rs 87 crore - The Times of India
- 10 days ago - Syngene International Q1 Results: Revenue grows 11% YoY to Rs 790 crore, Net profit jumps 59% YoY - Business Upturn
- 7 weeks ago - Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification - Business Upturn
- 3 months ago - Why are Syngene shares down 10% despite Q4 net profit jumping 2.8% YoY? - Business Upturn
- 3 months ago - Syngene International shares hit lower circuit crashing to 10% today after Q4 results - Business Upturn
- 5 months ago - Syngene International shares down 2.50% after USFDA issues Form 483 with five observations - Business Upturn
- 5 months ago - Suven Pharmaceuticals shares surge 12% as Macquarie initiates ‘Outperform’ rating with target price of Rs 1,500, estimating 29.9% upside potential - Business Upturn